Careers  |  Sign In  |  Register

Latest in Men’s Health

Reuters reports that U.S. health regulators have agreed to allow Repros Therapeutics Inc. to remove one of their clinical trial sites that was found markedly different from 16 other sites and to enroll 40 new patients. The company is now “on track to report trial data in the third quarter and sending its...
An article in The New York Times provides exciting results from a study that found “Men with high-risk prostate cancer treated with only 18 months of hormone therapy live just as long as those treated for a more standard 36 months.” Shorter treatment means fewer months of unpleasant side effects for...
A new study in Cancer characterizes the link between exercise and prostate cancer (CaP) in white and black American men. Researchers found "Higher amounts of MET (metabolic equivalent) hours per week were associated with a decreased risk of CaP for white men ... Among whites, men who exercised ≥ 9 MET...